SUPPLEMENTAL MATERIALS

Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO phase 2b/3 and ALLEGRO-LT phase 3 clinical studies

Maryanne Senna,[1] Jennifer Soung[2], Ignasi Figueras,[3] Brett King,[4] Misaki Kinoshita-Ise,[5] Sameh Hanna,[6] Wenyu Wu,[7] Dalia Wajsbrot,[8] Deborah Woodworth,[9] Robert Wolk,[8] Alanna Chaudhry,[9] Alexandre Lejeune,[10] Helen Tran[11]

[1]Lahey Hospital and Medical Center, Burlington, MA, USA; [2]Southern California Dermatology, Inc, Santa Ana, CA, USA and Harbor University of California Los Angeles, CA, USA; [3]Bellvitge Hospital, University of Barcelona, Barcelona, Spain; [4]Dermatology Physicians of Connecticut, Fairfield, CT, USA; [5]Department of Dermatology, Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo, Japan; [6]University of Toronto, Toronto, Ontario, Canada; [7]Huashan Hospital, Fudan University, Shanghai, China; [8]Pfizer Inc, Groton, CT, USA; [9]Pfizer Inc, Collegeville, PA, USA; [10]Pfizer Inc, Paris, France; [11]Pfizer Inc, New York, NY, USA

Corresponding author:

Helen Tran, PharmD
Helen.Tran@pfizer.com

Fig. S1 Proportions of patients with SALT score ≤20 response among **(A)** patients with AT/AU and **(B)** patients with non-AT/AU at baseline, and proportions of patients with SALT score ≤10 response among **(C)** patients with AT/AU and **(D)** patients with non-AT/AU at baseline



AT, alopecia totalis; AU, alopecia universalis; LOCF, last observation carried forward; SALT, Severity of Alopecia Tool. Error bars represent 95% confidence intervals.

*To align timepoints across groups for summarization, visits are calculated as time since the first ritlecitinib dose; some patients received placebo for 24 weeks in ALLEGRO-2b/3 followed by ritlecitinib 50 mg for 24 weeks, while some received ritlecitinib 50 mg for 48 weeks in ALLEGRO-2b/3; the "Month 36-38" timepoint includes patients who were treated with ritlecitinib for 36 months and patients who were treated with ritlecitinib for 38 months.

†Number of patients with valid data at that analysis visit. LOCF was applied to each visit for all participants with missing data.

Fig. S2 Proportion of patients with **(A)** sustained SALT score ≤20 response* and **(B)** sustained SALT score ≤10 response* through Month 36-38 among patients with SALT score ≤20 or SALT score ≤10 response at Month 12, respectively, for all patients and by baseline SALT score



LOCF, last observation carried forward; SALT, Severity of Alopecia Tool.

*Sustained SALT ≤20 response was defined as having response at Month 12 and sustaining this response through the Month 36-38 visit, without having a SALT >20 response at any timepoint in between. Sustained SALT ≤10 response was defined as having response at Month 12 and sustaining this response through the Month 36-38 visit, without having a SALT >10 response at any timepoint in between.

Fig. S3 Individual SALT score trajectories of patients who *maintained* SALT score ≤20 response from Month 12 to Month 36-38 but had a SALT score >20 between Months 12 and 36 (observed data)



SALT, Severity of Alopecia Tool.

*To align timepoints across groups for summarization, visits are calculated as time since the first ritlecitinib dose; some patients received placebo for 24 weeks in ALLEGRO-2b/3 followed by ritlecitinib 50 mg for 24 weeks, while some received ritlecitinib 50 mg for 48 weeks in ALLEGRO-2b/3; the "Month 36-38" timepoint includes patients who were treated with ritlecitinib for 36 months and patients who were treated with ritlecitinib for 38 months.

Fig. S4 Mean change from baseline in SALT score among **(A)** patients with AT/AU at baseline and **(B)** patients with non-AT/AU at baseline



AU, alopecia universalis; AT, alopecia totalis; LOCF, last observation carried forward; SALT, Severity of Alopecia Tool.

*To align timepoints across groups for summarization, visits are calculated as time since the first ritlecitinib dose; some patients received placebo for 24 weeks in ALLEGRO-2b/3 followed by ritlecitinib 50 mg for 24 weeks, while some received ritlecitinib 50 mg for 48 weeks in ALLEGRO-2b/3; the "Month 36-38" timepoint includes patients who were treated with ritlecitinib for 36 months and patients who were treated with ritlecitinib for 38 months.

†Number of patients with valid data at that analysis visit. LOCF was applied to each visit for all participants with missing data.

Fig. S5 Proportion of patients with EBA response among **(A)** patients with baseline SALT 50 to <95, **(B)** patients with baseline SALT 95-100, and **(C)** patients with baseline AT/AU



AT, alopecia totalis; AU, alopecia universalis; EBA, Eyebrow Assessment; LOCF, last observation carried forward; SALT, Severity of Alopecia Tool. Error bars represent 95% confidence intervals.

*To align timepoints across groups for summarization, visits are calculated as time since the first ritlecitinib dose; some patients received placebo for 24 weeks in ALLEGRO-2b/3 followed by ritlecitinib 50 mg for 24 weeks, while some received ritlecitinib 50 mg for 48 weeks in ALLEGRO-2b/3; the "Month 36-38" timepoint includes patients who were treated with ritlecitinib for 36 months and patients who were treated with ritlecitinib for 38 months.

†Number of patients with valid data at that analysis visit. LOCF was applied to each visit for all participants with missing data.

Fig. S6 Proportion of patients with ELA response among **(A)** patients with baseline SALT 50 to <95, **(B)** patients with baseline SALT 95-100, and **(C)** patients with baseline AT/AU



AT, alopecia totalis; AU, alopecia universalis; ELA, Eyelash Assessment; LOCF, last observation carried forward; SALT, Severity of Alopecia Tool. Error bars represent 95% confidence intervals.

*To align timepoints across groups for summarization, visits are calculated as time since the first ritlecitinib dose; some patients received placebo for 24 weeks in ALLEGRO-2b/3 followed by ritlecitinib 50 mg for 24 weeks, while some received ritlecitinib 50 mg for 48 weeks in ALLEGRO-2b/3; the "Month 36-38" timepoint includes patients who were treated with ritlecitinib for 36 months and patients who were treated with ritlecitinib for 38 months.

†Number of patients with valid data at that analysis visit. LOCF was applied to each visit for all participants with missing data.

Fig. S7 Proportion of patients with PGI-C response among **(A)** patients with baseline SALT 50 to <95, **(B)** patients with baseline SALT 95-100, and **(C)** patients with baseline AT/AU



AT, alopecia totalis; AU, alopecia universalis; LOCF, last observation carried forward; PGI-C, Patient Global Impression of Change; SALT, Severity of Alopecia Tool. Error bars represent 95% confidence intervals.

*To align timepoints across groups for summarization, visits are calculated as time since the first ritlecitinib dose; some patients received placebo for 24 weeks in ALLEGRO-2b/3 followed by ritlecitinib 50 mg for 24 weeks, while some received ritlecitinib 50 mg for 48 weeks in ALLEGRO-2b/3; the "Month 36-38" timepoint includes patients who were treated with ritlecitinib for 36 months and patients who were treated with ritlecitinib for 38 months.

†Number of patients with valid data at that analysis visit. LOCF was applied to each visit for all participants with missing data.